.png)
.png)
Dosing Complete In Phase I Clinical Trial Of Ultra-Rapid Acting Insulin Product Candidate AT247 For Diabetes
Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels. This is to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypo and hyperglycaemia.
The double-blind, randomised, three-way cross over Phase I clinical study compares the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial has been conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research and preliminary results are expected in Q4 2019.
Sarah Howell, Chief Executive Officer at Arecor, said: "The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes. I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Mo PR Advisory www.mopradvisory.com
Mo Noonan Mob: +44 (0) 7876 444977
Email: [email protected]
Notes to Editors
About Arecor
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
ArestatTM is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arecor’s proprietary products leverage ArestatTM to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates. Our clinical programmes are significantly de-risked because we reformulate existing approved products with known safety and efficacy profiles.
For our partners, we use ArestatTM to deliver superior reformulations of their proprietary products, which would otherwise not be possible.
For further details please see our website, www.arecor.com
Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels. This is to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypo and hyperglycaemia.
The double-blind, randomised, three-way cross over Phase I clinical study compares the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial has been conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research and preliminary results are expected in Q4 2019.
Sarah Howell, Chief Executive Officer at Arecor, said: "The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes. I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Mo PR Advisory www.mopradvisory.com
Mo Noonan Mob: +44 (0) 7876 444977
Email: [email protected]
Notes to Editors
About Arecor
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
ArestatTM is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arecor’s proprietary products leverage ArestatTM to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates. Our clinical programmes are significantly de-risked because we reformulate existing approved products with known safety and efficacy profiles.
For our partners, we use ArestatTM to deliver superior reformulations of their proprietary products, which would otherwise not be possible.
For further details please see our website, www.arecor.com